Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359650 | 1.00 | MAP2K1 (0.42) | MAP2K1RAF1MAPK1CRBNFKBP5 | |
| SCHEMBL11103726 | 0.74 | CRBN (0.39) | MAP2K1CRBNFKBP5MEN1KMT2A | |
| SCHEMBL116223 | 0.72 | — | — | |
| SCHEMBL30253370 | 0.71 | CRBN (0.41) | MAP2K1CRBNFKBP5MEN1KMT2A | |
| SCHEMBL16485712 | 0.70 | CRBN (0.39) | MAP2K1CRBNFKBP5HSD17B10PDPK1 | |
| Methane SCHEMBL10972248 | 0.69 | — | — | |
| Charcoal, Activated SCHEMBL30614618 | 0.69 | — | — | |
| SCHEMBL502060 | 0.69 | ALDH1A1 (0.42) | CRBNFKBP5MEN1KMT2AALDH1A1 | |
| SCHEMBL2762093 | 0.69 | ALDH1A1 (0.42) | CRBNFKBP5MEN1KMT2AALDH1A1 | |
| SCHEMBL4376729 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414770-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414770-B2 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | MAP2K1 557/4885RAF1 1271/4885MAPK1 538/4885 |
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | MAP2K1 557/4885RAF1 1271/4885MAPK1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.